<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1728094/" ref="ordinalpos=3175&amp;ncbi_uid=880298&amp;link_uid=PMC1728094" image-link="/pmc/articles/PMC1728094/figure/F1/" class="imagepopup">Figure 1  .  From: Specific targeting of IL-6 signalling <span class="highlight" style="background-color:">pathway</span>: a new way to treat IBD?. </a></div><br /><div class="p4l_captionBody"> The receptor for IL-6 consists of the ligand binding component (IL-6R) and the signal-transducing gp130. The soluble form of the IL-6R may form a complex with IL-6 having the ability to bind gp130 (trans signaling) expressed by T cells and to activate the anti-apoptotic STAT-3 dependent genes bcl-2 and bcl-xl. In inflammatory diseases, targeting of IL-6 signaling pathway modulates inflammation at least in part through the regulation of T cell expansion and the expression of adhesion molecules. </div></div>